Skip to main content
SpringerLink
Log in

Cysteinyl leukotriene receptor type 1 antagonist montelukast protects against injury of blood–brain barrier

Inflammopharmacology volume 27, pages 933–940 (2019)Cite this article

Abstract

The blood–brain barrier (BBB) is formed by tightly connected cerebrovascular endothelial cells. Injury of human brain endothelial cells can cause disruption of the BBB and severe injury to brain tissue. Signals mediated cysteinyl leukotrienes (cysLTs) and their receptors are involved in a variety of pathological conditions. In the current study, our results show that oxygen glucose-deprivation/reoxygenation (OGD/R) induced the expression of leukotriene receptor type 1 (cysLT1R) in brain endothelial cells. Blockage of cysLT1R by its specific antagonist montelukast suppressed OGD/R-induced altered permeability of the human brain endothelial cell (EC) monolayer. Mechanistically, montelukast treatment reversed OGD/R-induced reduction of the tight junction proteins occludin and zonula occludens-1 (ZO-1). Montelukast also ameliorated OGD/R-induced reduction of inhibitors of matrix metalloproteinases (TIMPs), such as TIMP-1 and TIMP-2. On the other hand, montelukast suppressed the expression and production of matrix metalloproteinases (MMPs) and cytokines including MMP-2, MMP-9, interleukin 1β (IL-1β), tumor necrosis factor-α (TNF-α), and interleukin 6 (IL-6). Using a murine middle cerebral artery occlusion brain injury model, we demonstrated that the administration of montelukast improved the surgery-induced brain injury and protected against disruption of brain endothelial junction proteins such as occludin and ZO-1. Collectively, our data suggest that montelukast might confer protective roles against injury in brain endothelial cells.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

USD 39.95

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8

References

  • Bäck M (2007) The leukotriene receptor antagonist montelukast and its possible role in the cardiovascular field. Sci World J 7:1422–1439

    Article  Google Scholar 

  • Bäck M (2009) Leukotriene signaling in atherosclerosis and ischemia. Cardiovasc Drugs Ther 23(1):41–48

    Article  Google Scholar 

  • Biber N, Toklu HZ, Solakoglu S, Gultomruk M, Hakan T, Berkman Z, Dulger FG (2009) Cysteinyl-leukotriene receptor antagonist montelukast decreases blood–brain barrier permeability but does not prevent oedema formation in traumatic brain injury. Brain Inj 23(6):577–584

    Article  Google Scholar 

  • Camós S, Mallolas J (2010) Experimental models for assaying microvascular endothelial cell pathophysiology in stroke. Molecules 15(12):9104–9134

    Article  Google Scholar 

  • Colazzo F, Gelosa P, Tremoli E, Sironi L, Castiglioni L (2017) Role of the cysteinyl leukotrienes in the pathogenesis and progression of cardiovascular diseases. Mediat Inflamm 2017:2432958

    Article  Google Scholar 

  • Di X, Tang X, Di X (2017) Montelukast inhibits oxidized low-density lipoproteins (ox-LDL) induced vascular endothelial attachment: an implication for the treatment of atherosclerosis. Biochem Biophys Res Commun 486(1):58–62

    Article  CAS  Google Scholar 

  • Gelosa P, Colazzo F, Tremoli E, Sironi L, Castiglioni L (2017) Cysteinyl leukotrienes as potential pharmacological targets for cerebral diseases. Mediat Inflamm 2017:3454212

    Article  Google Scholar 

  • Gronert K, Martinsson-Niskanen T, Ravasi S, Chiang N, Serhan CN (2001) Selectivity of recombinant human leukotriene D4, leukotriene B4, and lipoxin A4 receptors with aspirin-triggered 15-epi-LXA4 and regulation of vascular and inflammatory responses. Am J Pathol 158:3–9

    Article  CAS  Google Scholar 

  • Hoxha M, Capra V, Malaj V, Sala A, Rovati G (2017) The role of montelukast in cardiovascular events. Atherosclerosis 06:478

    Google Scholar 

  • Iadecola C, Anrather J (2011) The immunology of stroke: from mechanisms to translation. Nat Med 17(7):796–808

    Article  CAS  Google Scholar 

  • Ingelsson E, Yin L, Bäck M (2012) Nationwide cohort study of the leukotriene receptor antagonist montelukast and incident or recurrent cardiovascular disease. J Allergy Clin Immunol 129(3):702–707

    Article  CAS  Google Scholar 

  • Lampl Y, Boaz M, Gilad R, Lorberboym M, Dabby R, Rapoport A (2007) Minocycline treatment in acute stroke: an open-label, evaluator-blinded study. Neurology 69(14):1404–1410

    Article  CAS  Google Scholar 

  • Lee KS, Kim SR, Park HS, Jin GY, Lee YC (2004) Cysteinyl leukotriene receptor antagonist regulates vascular permeability by reducing vascular endothelial growth factor expression. J Allergy Clin Immunol 114:1093–1099

    Article  CAS  Google Scholar 

  • Longa EZ, Weinstein PR, Carlson S, Cummins R (1989) Reversible middle cerebral artery occlusion without craniectomy in rats. Stroke 20(1):84–91

    Article  CAS  Google Scholar 

  • Maekawa A, Austen KF, Kanaoka Y (2002) Targeted gene disruption reveals the role of cysteinyl leukotriene 1 receptor in the enhanced vascular permeability of mice undergoing acute inflammatory responses. J Biol Chem 277(23):20820–20824

    Article  CAS  Google Scholar 

  • Mergenthaler P, Lindauer U, Dienel GA, Meisel A (2013) Sugar for the brain: the role of glucose in physiological and pathological brain function. Trends Neurosci 36(10):587–597

    Article  CAS  Google Scholar 

  • Peters-Golden M, Gleasonw MM, Togias A (2006) Cysteinyl leukotrienes: multi-functional mediators in allergic rhinitis. Clin Exp Allergy 36(6):689–703

    Article  CAS  Google Scholar 

  • Pologe LG, Cramer EB, Pawlowski NA, Abraham E, Cohn ZA, Scott WA (1984) Stimulation of human endothelial cell prostacyclin synthesis by select leukotrienes. J Exp Med 160:1043–1053

    Article  CAS  Google Scholar 

  • Riccioni G, Bäck M (2012) Leukotrienes as modifiers of preclinical atherosclerosis? Sci World J 2012:490968

    Article  Google Scholar 

  • Ronaldson PT, Davis TP (2015) Targeting transporters: promoting blood–brain barrier repair in response to oxidative stress injury. Brain Res 1623:39–52

    Article  CAS  Google Scholar 

  • Shi H, Sheng B, Zhang F, Wu C, Zhang R, Zhu J, Xu K, Kuang Y, Jameson SC, Lin Z, Wang Y, Chen J, Jain MK, Atkins GB (2013) Kruppel-like factor 2 protects against ischemic stroke by regulating endothelial blood brain barrier function. Am J Physiol Heart Circ Physiol 304:H796–H805

    Article  CAS  Google Scholar 

  • Virchow JC, Faehndrich S, Nassenstein C, Bock S, Matthys H, Luttmann W (2001) Effect of a specific cysteinyl leukotriene-receptor 1-antagonist (montelukast) on the transmigration of eosinophils across human umbilical vein endothelial cells. Clin Exp Allergy 31(6):836–844

    Article  CAS  Google Scholar 

  • Yu GL, Wei EQ, Zhang SH, Xu HM, Chu LS, Zhang WP, Zhang Q, Chen Z, Mei RH, Zhao MH (2005) Montelukast, a cysteinyl leukotriene receptor-1 antagonist, dose- and time-dependently protects against focal cerebral ischemia in mice. Pharmacology 73(1):31–40

    Article  CAS  Google Scholar 

  • Zhang YY, Walker JL, Huang A, Keaney JF, Clish CB, Serhan CN, Loscalzo J (2002) Expression of 5-lipoxygenase in pulmonary artery endothelial cells. Biochem J 361:267–276

    Article  CAS  Google Scholar 

  • Zhang W, Hu H, Zhang L, Chen Z, Wei E (2004) Expression of cysteinyl leukotriene receptor 1 in human traumatic brain injury and brain tumors. Neurosci Lett 363(3):247–251

    Article  CAS  Google Scholar 

  • Zhao R, Shi WZ, Zhang YM, Fang SH, Wei EQ (2011) Montelukast, a cysteinyl leukotriene receptor-1 antagonist, attenuates chronic brain injury after focal cerebral ischaemia in mice and rats. J Pharm Pharmacol 63(4):550–557

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We thank the research fund from Weifang People’s Hospital.

Author information

Authors and Affiliations

  1. Department of Neurology, Weifang People’s Hospital, No. 5, Guangwen Street, Kuiwen District, Weifang, 261000, Shandong, China

    Li Zhou, Xiaomin Sun, Yong Shi, Junpeng Liu, Guohui Luan & Yanwen Yang

Authors
  1. Li Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Xiaomin Sun
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yong Shi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Junpeng Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Guohui Luan
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yanwen Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yanwen Yang.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zhou, L., Sun, X., Shi, Y. et al. Cysteinyl leukotriene receptor type 1 antagonist montelukast protects against injury of blood–brain barrier. Inflammopharmacol 27, 933–940 (2019). https://doi.org/10.1007/s10787-019-00611-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10787-019-00611-7

Keywords

search

Navigation